CJC-1295 DAC A Full Analysis

Various modifications have been made to growth hormone-releasing hormone (GHRH) to develop analogs that may maintain some of the potential properties and actions of the hormone while removing others. Only the first 29 amino acids of GHRH are included in one of these changes, denoted by the acronym CJC-1295. In an attempt to make a more soluble GH secretagogue that is simpler to manufacture in large amounts while still preserving the physiologic activities of GHRH, this analog of GHRH, which is technically a maleimido derivative of hGRF(1-29), was developed. This was done to build a more soluble GH secretagogue.

CJC-1295 vs. CJC-1295 DAC

Being a modified form of the first 29 amino acids of GHRH, CJC-1295 is chemically comparable to other GHRH analogs, such as Sermorelin. The two peptides differ even though they are most comparable to modified GRF (1-29). A significant misunderstanding emerges because of the similarities between these peptides and the fact that CJC-1295 was first developed with an additional chemical molecule known as the affinity complex (DAC).

DAC is incorporated into the molecule with the assistance of a lysine linker to safeguard the peptide while it is being transported through the circulatory system. DAC contributes to the fact that the half-life of CJC-1295 is much longer than comparable compounds such as GRF (1-29). This is accomplished by enabling peptides to attach to albumin, a common blood protein.

ConjuChem Biotechnologies, the company responsible for developing DAC, first referred to the molecule containing DAC as CJC-1295. However, confusion began to arise because the peptide was also marketed without DAC. The CJC-1295 that does not have DAC is called CJC-1295 or CJC-1295-no DAC. This is done to prevent any mistake from arising.

CJC-1295 Peptide and hGH

Research indicates that because it is a derivative of GHRH, the proposed action that CJC-1295 may have to encourage the release of GH should not come as a surprise. A single concentration of CJC-1295 has been suggested to boost growth hormone (GH) levels in mice by a factor of two to ten. After delivery, peak growth hormone (GH) levels are attained roughly two hours later, and the effects continue for approximately six days. Investigations purport that the normal physiologic release of growth hormone may be maintained by CJC-1295, in contrast to other GH secretagogues. This indicates that the usual circadian peaks and valleys seen in the growth hormone release may be preserved and that CJC 1295 is a physiologic growth hormone-releasing factor.

To guarantee improved results without a corresponding rise in adverse effects, it is essential to maintain the physiologic release of growth hormone (GH) while simultaneously affecting the maximum concentration of the hormone in the circulation. In particular, it has been speculated that CJC-1295 may sustain possible physiological effects of growth hormone on hyperplasia, hypertrophy, bone density, blood sugar, fat metabolism, protein synthesis, and the function of myocardial cells (heart cells).

CJC-1295 Peptide and GHRH

Research conducted on mice which do not have proper GHRH physiology has indicated that CJC-1295 may maintain normal GH release. Given this, the peptide has been hypothesized to potentially be impactful in research within the context of aberrant growth in a wide range of mammalian species. To ensure that downstream hormones, such as insulin-like growth factor-2 (IGF-1), are released appropriately, it is essential to maintain the regular pulsatile release of growth hormone (GH).

CJC-1295 Peptide and Infertility

Findings imply that CJC-1295 and other GRF analogs may be useful in inducing ovulation in infertile female animals. The fact that ovulation is reliant on IGF-1 and that it is likely also regulated by GH release and cycling has been documented by scientists for a considerable amount of time. The findings of studies conducted on animal models of superovulation have contributed to the validation of these hypotheses by suggesting that levels of both GH and IGF-1 may considerably increase in the vicinity of the time of ovulation. In addition, the findings of these investigations suggest that GH secretagogues, such as CJC-1295, might be sufficient to induce ovulation optimally. There is a school of thought that suggests CJC-1295 and its analogs might potentially be effective in the context of male animal infertility by assisting in the regulation of sperm production. A test has not yet been conducted on this latter notion.

CJC-1295 Peptide Summary

Scientists speculate that a growth hormone secretagogue known as CJC-1295 was developed to preserve the physiologic patterns inherent in the GH axis while also having a lengthy plasma half-life span. The success of the molecule may be attributed to both of these aspects. Even though several compounds are quite similar to CJC-1295, there has been very little interest in the molecule in research settings. This is because the structure of the molecule is private. There is expected to be a resurgence of interest in the qualities of CJC-1295 now that it is possible to make it at will. This is especially true regarding how these features relate to the increasingly vexing issue of infertility.

Core Peptides is the optimal place to get CJC-1295 DAC; it is not intended for human consumption but solely for educational and scientific research. Purchasing CJC-1295 is only permitted if you are a licensed researcher.

References

[i] M. Ionescu and L. A. Frohman, “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog,” J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792–4797.

[ii] Alba et al., “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse,” Am. J. Physiol. Endocrinol. Metab., vol. 291, no. 6, pp. E1290-1294. 2 Pro duct List C

[iii] A. Volpe, G. Coukos, A. Barreca, G. Giordano, P. G. Artini, and A. R. Genazzani, “Clinical use of growth hormone-releasing factor for induction of superovulation,” Hum. Reprod., vol. 6, no. 9, pp. 1228–1232.

[iv] Jetté, Lucie & Leger, Roger & Thibaudeau, Karen & Benquet, Corinne & Robitaille, Martin & Pellerin, Isabelle & Paradis, Véronique & Wyk, Pieter & Pham, Khan & Bridon, Dominique. (2005). hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long Lasting GRF Analog. 4